The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review
Open accessAbstract
Obesity is a chronic disease with increasing prevalence. It affects quality of life and renders those affected at increased risk of mortality. For people living with obesity, weight loss is one of the most important strategies to improve health outcomes and prevent or reverse obesity-related complications. In line with newly released clinical practice guidelines, weight loss targets for people living with obesity should be defined individually based on their clinical profile, and progress measured in the context of improvements in health outcomes, rather than weight loss alone. We outline current treatment options for clinically meaningful weight loss and briefly discuss pharmacological agents and devices under development. Numerous studies have shown that weight loss of ≥5% results in significant improvements in cardiometabolic risk factors associated with obesity; this degree of weight loss is also required for the approval of novel anti-obesity medications by the US Food and Drug Administration. However, some obesity-related comorbidities and complications, such as non-alcoholic steatohepatitis, obstructive sleep apnea, gastroesophageal reflux disease and remission of type 2 diabetes, require a greater magnitude of weight loss to achieve clinically meaningful improvements. In this review, we assessed the available literature describing the effect of categorical weight losses of ≥5%, ≥10%, and ≥15% on obesity-related comorbidities and complications, and challenge the concept of clinically meaningful weight loss to go beyond percentage change in total body weight. We discuss weight-loss interventions including lifestyle interventions and therapeutic options including devices, and pharmacological and surgical approaches as assessed from the available literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over 5% weight loss is considered clinically meaningful [38]”
From One‐Year Weight Loss Following a Remote Culinary Medicine Program: A Bi‐Center Randomized Controlled Trial (2026) · cites this paper as [38]
In the citing paper
“GERD amelioration might require ≥10% BW loss, which is hardly achievable and sustainable without pharmacotherapy108.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“2% following intensive lifestyle interventions in individuals with overweight or obesity with impaired glucose tolerance was associated with a 58% reduction in T2D incidence [57,84].”
BackgroundHealth effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8 mg shows improvements in both NASH and cardiovascular risk factors [73,104].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“Typically, weight loss with AOMs is progressive for 36–56 weeks and sustained thereafter if medication is continued [32,34,35,39].”
BackgroundDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 5×
“T2D in those who had intensive lifestyle interventions was reduced by 34% in a 10-year follow-up study of the Diabetes Prevention Program [85].”
BackgroundInfluentialJensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · cited 1×
“≥10% weight loss Weight loss of 7–10% resulted in significant improvements in NAS and resolution of NASH in patients who were men, or with BMI <35 kg/m(2) without diabetes; however, in women or those with greater BMI, diabetes, and other risk factors, weight loss of ≥10% was required for NAS improvement [106].”
BackgroundGarg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Research works printed but not linked: 5
- Yuen M, 2016, Oral presentation T-P-3166 presented at: Obesity Week 2016
- Horn D, 2020, Oral presentation presented at: 5th Annual Diabetes, Obesity, and Metabolic Disease Conference
- Horn D, 2020, Oral presentation presented at: Board Review Course. Annual Columbia/Cornell Obesity: Etiology, Prevention and Treatment Course; Virtual
- Lau D, 2020, Oral presentation 043 presented at: Obesity Week 2020; Virtual
- American Medical Association. Recognition of obesity as a disease 2013 [cited 2021 Sept 1]. Available from: https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-0-3858.xml
Cited by
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Blüher, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16263 · Cited by 175
“75,83 There are still several obstacles to translate current knowledge about the causes of obesity and modern treatment options for people living with obesity.”
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00182-7 · Cited by 176
Mu, Y., Bao, X., Eliaschewitz, F. G., Hansen, M. R., Kim, B. T., Koroleva, A., Ma, R. C. W., Yang, T., Zu, N., & Liu, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00388-1 · Cited by 133
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Metadata
- Authors
- Horn, D. B., Almandoz, J. P., & Look, M.
- Affiliations
- Department of Surgery, University of Texas McGovern Medical School, Houston, TX, USA
- The University of Texas Southwestern Medical Center (US)
- Family Health Centers of San Diego (US)
- Corresponding author
- Horn, Deborah B.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2022-04-26
- Volume
- 134
- Issue
- 4
- Pages
- 359-375
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W4220745397
- Cited by
- 114
- References
- 120
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 22 · 2023: 14 · 2022: 3
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Postgraduate Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss, weight loss targets, anti-obesity drugs, bariatric surgery, lifestyle intervention, cardiometabolic risk, type 2 diabetes remission, nonalcoholic steatohepatitis, obstructive sleep apnea, gastroesophageal reflux disease, obesity-related comorbidities
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Quality of Life, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. https://app.cochat.ai/papers/10.1080/00325481.2022.2051366
- The paper
- Horn, D. B., Almandoz, J. P., & Look, M. (2022). What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgraduate Medicine. https://doi.org/10.1080/00325481.2022.2051366
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.